RESUMEN
AIM: Drug-coated balloon (DCB) technology has emerged as a promising therapy particularly in the treatment of coronary in-stent restenosis. Although a variety of devices are available for clinical use, clinical outcomes have been variable and scope for significant improvement exists. METHODS: In a preclinical study, a total of 10 juvenile healthy farm pigs underwent catheter-based DCB deployment in coronary arteries with angiographic and pathological follow-up at 7 or 28 days. Animals were randomly allocated to the PRIMUS or Dior® DCB (N.=10 per group) and evaluated by histopathology and morphometric analysis. In a first-in-man clinical study a total of 19 consecutive patients presenting with restenosis within drug-eluting stents were treated with the PRIMUS DCB. Clinical follow-up was performed out to 6 months. RESULTS: Neointimal thickness was similar between the PRIMUS and Dior® DCB groups, while fibrin deposition and inflammation were more sustained in the PRIMUS group at 28 days. In 19 consecutive patients presenting with in-stent restenosis of drug-eluting stents, treatment with the PRIMUS DCB catheter resulted in high procedural efficacy. There were no adverse clinical events observed out to 6 months. CONCLUSION: The PRIMUS DCB demonstrates high preclinical safety and excellent acute performance and safety. Further studies are needed to delineate the relative merits of this novel DCB compared to other devices.
Asunto(s)
Angioplastia de Balón/instrumentación , Materiales Biocompatibles Revestidos , Reestenosis Coronaria/terapia , Anciano , Animales , Catéteres , Estudios de Seguimiento , Humanos , Masculino , PorcinosRESUMEN
The advent of drug-eluting balloon (DEB) therapy has represented an important development in interventional cardiology. Nevertheless, preclinical data with this technology remain scant, and comparative studies have not previously been published. Bare metal stents were implanted in the coronary arteries of 15 pigs followed by balloon angioplasty. Animals were allocated to treatment with a 60-second inflation of one of four different balloon catheters: a conventional untreated plain angioplasty balloon (PBA, Biotronik AG), the Pantera Lux DEB (3.0 µg/mm2 paclitaxel; BTHC excipient, Biotronik AG), the Elutax DEB (2.0 µg/mm2 paclitaxel; no excipient; Aachen Resonance), or the SeQuent Please DEB (3.0 µg/mm2 paclitaxel; iopromide excipient: B. Braun). Twenty-eight days following balloon deployment, animals underwent repeat angiography for quantitative coronary angiography analysis and euthanasia for histopathologic assessment. By histology, the mean neointimal thickness was 0.44 ± 0.19 mm with PBA, 0.35 ± 0.13 mm with Pantera Lux , 0.61 ± 0.20 mm with Elutax , and 0.47 ± 0.21 mm with SeQuent Please DEB (p=0.02). In comparison with PBA, deployment of the Pantera Lux or the SeQuent Please DEB resulted in delayed healing characterised by significant increases in fibrin, neointimal cell vacuity and delayed re-endothelialisation. In conclusion, investigation of comparative DEB performance in a porcine model of advanced coronary restenosis reveals significant heterogeneity of neointimal suppression between the devices tested with numerically lowest values seen in the Pantera Lux group. On the other hand, evidence of delayed healing was observed in the most effective DEB groups.
Asunto(s)
Angioplastia de Balón , Reestenosis Coronaria/terapia , Estenosis Coronaria/terapia , Vasos Coronarios/patología , Endotelio Vascular/metabolismo , Animales , Reestenosis Coronaria/etiología , Reestenosis Coronaria/patología , Reestenosis Coronaria/fisiopatología , Estenosis Coronaria/complicaciones , Estenosis Coronaria/patología , Estenosis Coronaria/fisiopatología , Vasos Coronarios/efectos de los fármacos , Vasos Coronarios/cirugía , Modelos Animales de Enfermedad , Stents Liberadores de Fármacos/efectos adversos , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/patología , Fibrina/metabolismo , Humanos , Neointima , Paclitaxel/administración & dosificación , Porcinos , Cicatrización de Heridas/efectos de los fármacosRESUMEN
The adenomatous polyposis coli (APC) tumor suppressor is inactivated by mutation in most colorectal tumors. APC is a component of the Wnt signaling pathway and is best known for its ability to downregulate beta-catenin and consequent effects on transcriptional regulation. Previous work demonstrated that APC accelerates apoptosis-associated caspase activity independently of transcription, and suggested novel tumor suppressor functions of APC. In this work, we have mapped the APC apoptosis-accelerating region to amino acids (aa) 1-760 by testing a series of non-overlapping APC segments. Interestingly, this segment corresponds to a stable group II caspase cleavage product of APC released during apoptosis that includes the amino-terminal aa1-777. Mutation of the APC aspartic acid residue at position 777 to an alanine completely abolished in vitro cleavage of APC by a recombinant group II caspase and rendered the full-length protein unable to accelerate apoptosis in vitro. A truncated APC protein associated with familial and sporadic colorectal cancer, also unable to accelerate apoptosis in vitro and in vivo, is resistant to group II caspase cleavage. These results demonstrate that cleavage of APC and the subsequent release of an amino-terminal segment are necessary for the transcription-independent mechanism of APC-mediated apoptosis.
Asunto(s)
Proteína de la Poliposis Adenomatosa del Colon/metabolismo , Apoptosis/fisiología , Caspasas/metabolismo , Fragmentos de Péptidos/metabolismo , Proteína de la Poliposis Adenomatosa del Colon/química , Proteína de la Poliposis Adenomatosa del Colon/genética , Apoptosis/genética , Western Blotting , Caspasa 3/genética , Caspasa 3/metabolismo , Caspasas/genética , Línea Celular Tumoral , Proteínas Fluorescentes Verdes/genética , Proteínas Fluorescentes Verdes/metabolismo , Humanos , Luciferasas/genética , Luciferasas/metabolismo , Peso Molecular , Mutación , Fragmentos de Péptidos/química , Fragmentos de Péptidos/genética , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Proteínas Recombinantes/metabolismo , Transcripción Genética , Transfección , beta Catenina/metabolismoAsunto(s)
Empalme Alternativo , Proteínas del Citoesqueleto/genética , Neoplasias Neuroepiteliales/genética , Neuronas/metabolismo , Proteína de la Poliposis Adenomatosa del Colon , Animales , Células Cultivadas , Cerebelo/citología , Cerebelo/metabolismo , ADN/química , ADN/genética , Análisis Mutacional de ADN , Expresión Génica , Glioblastoma/genética , Glioblastoma/patología , Humanos , Meduloblastoma/genética , Meduloblastoma/patología , Mutación , Neoplasias Neuroepiteliales/patología , Neuronas/citología , Polimorfismo Conformacional Retorcido-Simple , ARN/genética , ARN/metabolismo , Ratas , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Médula Espinal/citología , Médula Espinal/embriología , Médula Espinal/metabolismo , Células Tumorales CultivadasRESUMEN
The influence of sepsis on transcription of myofibrillar proteins in skeletal muscle was studied in rats. Sepsis was induced by cecal ligation and puncture (CLP); control rats were sham-operated. Sixteen hours later, muscle levels of mRNA for myofibrillar proteins were determined by using cDNA probes specific for transcripts for alpha actin and myosin heavy chain. Sepsis resulted in a 2-6 fold decrease in alpha actin mRNA levels and an even more pronounced reduction in myosin heavy chain mRNA levels. Results suggest that sepsis-induced reduction of muscle protein synthesis is at least partly regulated at the transcriptional level.